All In Biotech

NDA 016324 · Legacy

Imuran

Azathioprine · Oral · Purine Antimetabolite

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1968

Mar 20, 1968

Approved uses

2

Original approval plus efficacy supplements

Registered trials

250

84 Phase 3, 33 recruiting

FAERS reports

88,646

76,823 serious, 8,939 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING - MALIGNANCY Chronic immunosuppression with IMURAN, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with IMURAN. See WARNINGS.

What it is approved for

From the label in effect Mar 19, 2026.

INDICATIONS AND USAGE: IMURAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation: IMURAN is indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables. The effect of IMURAN on these variables has not been tested in controlled trials. Rheumatoid Arthritis: IMURAN is indicated for the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. Aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with IMURAN. The combined use of IMURAN with disease modifying anti-rheumatic drugs (DMARDs) has not been studied for either added benefit or unexpected adverse effects. The use of IMURAN with these agents cannot be recommended.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 13, 1981 Supplement 10 · Efficacy
  • Mar 20, 1968 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • IMURAN · AZATHIOPRINE 25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • IMURAN · AZATHIOPRINE 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Azathioprine" as an intervention, any sponsor and status, largest first.

All 250 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use13,597
  • drug ineffective13,160
  • condition aggravated6,671
  • arthralgia5,928
  • diarrhoea5,574
  • nausea5,296
  • fatigue5,228
  • headache4,493
  • crohn^s disease4,362
  • pain4,291
  • pyrexia4,105
  • pneumonia4,021

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004980
2005798
2006894
2007967
20081,529
20091,603
20101,724
20112,441
20123,071
20133,073
20143,530
20153,922
20164,331
20174,273
20185,733
20196,600
20207,710
20216,295
20226,419
20235,922
20246,566
20256,379
20263,873

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Imuran (Azathioprine)

2024 spending

$461K

Beneficiaries

101

453 claims

Per beneficiary

$4,565

$8.43 per unit

View as table
YearSpending
2020$589,582
2021$529,864
2022$467,937
2023$434,393
2024$461,115

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,068 on PubMed

Sponsor: Legacy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.